Advaxis Inc. (ADXS)

0.32
0.03 9.20
NASDAQ : Health Technology
Prev Close 0.35
Open 0.35
Day Low/High 0.31 / 0.35
52 Wk Low/High 0.18 / 3.29
Volume 365.59K
Avg Volume 779.30K
Exchange NASDAQ
Shares Outstanding 69.62M
Market Cap 24.22M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Advaxis To Host Business Update Conference Call On January 15, 2019

Advaxis To Host Business Update Conference Call On January 15, 2019

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Tuesday, January 15, 2019.

Advaxis To Present At LD Micro Main Event

Advaxis To Present At LD Micro Main Event

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Advaxis To Present Poster Entitled "Natural Killer (NK) Cells Orchestrate The Antitumor Activities Of Listeria Monocytogenes (Lm)-Based Immunotherapy" At Society For Immunotherapy Of Cancer Annual Meeting

Advaxis To Present Poster Entitled "Natural Killer (NK) Cells Orchestrate The Antitumor Activities Of Listeria Monocytogenes (Lm)-Based Immunotherapy" At Society For Immunotherapy Of Cancer Annual Meeting

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC).

Advaxis Provides Update On Clinical Pipeline

Advaxis Provides Update On Clinical Pipeline

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it will be continuing its ongoing Phase 3, randomized, double-blinded,...

Advaxis To Host Business Update Conference Call On November 2, 2018

Advaxis To Host Business Update Conference Call On November 2, 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018.

Advaxis To Present At The Cantor Fitzgerald Global Healthcare Conference

Advaxis To Present At The Cantor Fitzgerald Global Healthcare Conference

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Advaxis Announces Closing Of Its Public Offering Of Common Stock And Warrants

Advaxis Announces Closing Of Its Public Offering Of Common Stock And Warrants

  Advaxis, Inc. (NASDAQ: ADXS) ("Advaxis" or the "Company") announced today the closing of its previously announced underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock.

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights And Financial Results

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights And Financial Results

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced business highlights and financial results for the fiscal year 2018 third quarter, ended...

Advaxis Announces Pricing Of Its Public Offering Of Common Stock And Warrants

Advaxis Announces Pricing Of Its Public Offering Of Common Stock And Warrants

Advaxis, Inc. (NASDAQ:ADXS) ("Advaxis" or the "Company") announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock.

Advaxis, Inc. Announces Proposed Underwritten Public Offering Of Common Stock And Warrants

Advaxis, Inc. Announces Proposed Underwritten Public Offering Of Common Stock And Warrants

Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company") announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a...

Advaxis Licenses ADXS-HER2 To OS Therapies For Evaluation In The Treatment Of Osteosarcoma

Advaxis Licenses ADXS-HER2 To OS Therapies For Evaluation In The Treatment Of Osteosarcoma

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, and OS Therapies LLC, a clinical-stage therapeutic company focused on the identification, development...

Advaxis Announces FDA Allowance Of IND Application For ADXS-HOT Drug Candidate For Non-Small Cell Lung Cancer

Advaxis Announces FDA Allowance Of IND Application For ADXS-HOT Drug Candidate For Non-Small Cell Lung Cancer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.

Advaxis Announces FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac With Durvalumab

Advaxis Announces FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac With Durvalumab

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.

Advaxis Provides Update On MAA Filing And ADXS-HOT Program

Advaxis Provides Update On MAA Filing And ADXS-HOT Program

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a clinical update, as follows: Plans to withdraw its Conditional Marketing Authorization...

Advaxis Announces Dosing Of First Patient With ADXS-NEO, An Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

Advaxis Announces Dosing Of First Patient With ADXS-NEO, An Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it has commenced a Phase 1 trial with the dosing of the first patient with ADXS-NEO, an...

Advaxis Announces Prioritization Of Product Portfolio And Reports Fiscal 2018 Second Quarter Financial Results

Advaxis Announces Prioritization Of Product Portfolio And Reports Fiscal 2018 Second Quarter Financial Results

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a new prioritization of its product portfolio, as well as financial results and...

Advaxis Appoints Molly Henderson As Chief Financial Officer

Advaxis Appoints Molly Henderson As Chief Financial Officer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment of Molly Henderson as Executive Vice President and Chief Financial...

Data Highlighting Advaxis' ADXS-PSA Presented At ASCO Annual Meeting

Data Highlighting Advaxis' ADXS-PSA Presented At ASCO Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer...

Recently Presented Preclinical Data Show Potential For ADXS-NEO As Anti-Cancer Immunotherapy Agent

Recently Presented Preclinical Data Show Potential For ADXS-NEO As Anti-Cancer Immunotherapy Agent

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of...

Kenneth A. Berlin, President, CEO And Director Of Advaxis, Inc. (Photo: Business Wire)

Kenneth A. Berlin, President, CEO And Director Of Advaxis, Inc. (Photo: Business Wire)

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Data Highlighting Advaxis' ADXS-PSA Accepted As Poster Presentation At The American Society Of Clinical Oncology Annual Meeting

Data Highlighting Advaxis' ADXS-PSA Accepted As Poster Presentation At The American Society Of Clinical Oncology Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has...

Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology At AACR 2018

Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology At AACR 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies...

Advaxis To Present At Upcoming March Conferences

Advaxis To Present At Upcoming March Conferences

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, announced today that Company...

Short Interest In Advaxis Drops 36.7%

Short Interest In Advaxis Drops 36.7%

The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 3,020,486 share decrease in total short interest for Advaxis Inc , to 5,217,154, a decrease of 36.67% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Advaxis Reports Fiscal 2018 First Quarter Financial Results And Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca's IMFINZI® (Durvalumab)

Advaxis Reports Fiscal 2018 First Quarter Financial Results And Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca's IMFINZI® (Durvalumab)

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces financial results for the three months ended...

Advaxis To Host Business Update And First Quarter 2018 Financial Results Conference Call On March 12, 2018

Advaxis To Host Business Update And First Quarter 2018 Financial Results Conference Call On March 12, 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLMN, CENX, MMYT, ULH, USM Downgrades: CVV, DGICA, DGICB, INT, MELI, RMAX, VLP Initiations: ADXS Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: E+ (Sell)